Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite significant reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia maybe an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides and the cholesterol content within triglyceride-rich lipoproteins (TGRL) and/or remnant cholesterol (RC) in the development of ASCVD. TGRL are comprised of hepatically derived very low-density lipoprotein (VLDL) and intestinally derived chylomicrons. RC is the cholesterol content of all TGRL and plasma triglycerides serve as a surrogate measure of TGRL and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive TG lowering efficacy. Several ongoing randomized controlled trials are under way to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology and genetics of triglycerides and ASCVD and discuss current and novel triglyceride lowering therapies under development.
Elevated low-density lipoprotein (LDL)-cholesterol (LDL-C) is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD) and is the primary target of therapy for primary and secondary prevention according to national and international guidelines (1) (2) (3) . Observational and genetic epidemiology consistently demonstrate that individuals with low plasma levels of LDL-C over the life course enjoy lower rates of ASCVD compared to those with average or high levels of LDL-C (4) (5) (6) (7) (8) . Moreover, the introduction of the statins 30 years ago provided the critical evidence linking significant LDL-C lowering to substantial reductions in ASCVD events (9). However, despite reductions in LDL-C with statins and newer lipid lowering agents, significant residual risk persists with the majority of predicted first and recurrent ASCVD events not being averted (10). Growing evidence suggests that triglycerides (TG) and/or the cholesterol content within triglyceride-rich lipoproteins (TGRL) may contribute to this residual risk (11). This notion is of particular interest as the burgeoning epidemics of obesity, metabolic syndrome, and diabetes are associated with a dramatic increase in the prevalence of hypertriglyceridemia and its potential intersection with ASCVD (12).
Historically, the relationship between TG and ASCVD has been controversial. Hypertriglyceridemia is frequently associated with concomitant lipoprotein alterations such as decreased high-density lipoprotein (HDL)-cholesterol (HDL-C) levels and elevated levels of non-HDL-C, small dense and total LDL particles, intermediate-density lipoprotein (IDL), and total apolipoprotein CIII, all of which are associated with increased ASCVD risk (13). All of this may confound the causal association between elevated TG levels and ASCVD. In addition, equivocal clinical trial results of TG lowering therapies have raised the question as to whether TG represent a surrogate for other causal mechanisms at play for atherosclerotic disease (12, [14] [15] [16] . Much of the emphasis over the past decade centered on the inverse relationship of HDL-C and ASCVD with large scale efforts aimed at elucidating the role of HDL in atheroprotection. However, evidence from Mendelian randomization studies and a series of failed randomized controlled cardiovascular outcomes trials suggest that HDL-C, while a useful biomarker of risk, may not be a causal risk factor for ASCVD (11, (17) (18) (19) (20) (21) (22) . These findings have led to a renewed interest in the role of TG and/or remnant cholesterol (RC) in the development of vascular disease. In this review, we discuss the epidemiology, genetics, and biology of TGRL, RC, and ASCVD, and provide an overview of current and novel TG-lowering therapies under development.
Population Distribution and Causes of Hypertriglyceridemia
Hypertriglyceridemia is commonly defined as a fasting serum TG level ≥ 150 mg/dL (1.7 mmol/L) (12). TG levels are classified as follows by the Adult Treatment Panel III of the National Cholesterol Education Program: borderline high (150-199 mg/dL), high (200-499 mg/dL) and very high (≥ 500 mg/dL) (23) . In the general population, TG distribution is skewed with a tail towards the highest levels compared to normal distribution of other lipid parameters such as total cholesterol, LDL-C, and HDL-C (24) . Data from the National Health and Nutrition Examination Survey (NHANES) demonstrated that approximately 31%, 16 .2% and 1.1% of the adult United States (US) population had TG levels ≥ 150 mg/dL, ≥ 200 mg/dL and ≥ 500 mg/dL, respectively (12, 25) . Mexican-Americans have the highest prevalence of hypertriglyceridemia across all categories of TG levels, followed by non-Hispanic whites and non-Hispanic blacks (12, 25) . Hypertriglyceridemia is a well-known cause of acute pancreatitis. Typically, the risk of acute pancreatitis increases progressively with fasting TG levels over 500 mg/dL, with a significant increase when TG levels exceed 1000 mg/dL. The lifetime risk of pancreatitis is about 5% and 10-20% with fasting TG levels >1000 mg/dL and >2000 mg/dL, respectively (26) . At these levels, chylomicrons are usually the main carriers of TG in plasma. Severe hypertriglyceridemia is associated with hyperviscosity in the pancreatic capillaries leading to ischemia and release of pancreatic lipases and toxic free fatty acids that cause inflammation and pancreatitis (27, 28) . Hypertriglyceridemia occurs due to increased TG production, altered processing and catabolism of TG-rich lipoproteins, or reduced clearance. Moderately elevated TG concentrations are commonly due to suboptimal lifestyle habits, including diets enriched in simple carbohydrates and/or saturated fats, excess alcohol consumption, obesity, and sedentary behavior. Excess alcohol consumption is associated with increased adipocyte lipolysis and flux of free fatty acids (FFA) to the liver resulting in increased very low density lipoprotein (VLDL) production (29) . Other secondary causes of hypertriglyceridemia include pregnancy, hypothyroidism, chronic kidney disease (CKD), poorly controlled diabetes and/or metabolic syndrome, and medications (11, 30) . In pregnancy, plasma triglycerides levels can increase 2-4fold during the third trimester due to physiologic hormonal changes and are generally not clinically significant (31). Increase in estrogen levels during the third trimester stimulates hepatic VLDL secretion and reduces the clearance of TG by lipoprotein lipases (LPL) in the liver and adipose tissues resulting in elevated TG levels (31). Thyroid hormone is an important regulator of LPL activity and elevated TG levels in hypothyroidism are due to decreased LPL activity (32) . Patients with CKD frequently have elevated TG levels due to diminished activity of LPL, reduced clearance of TGRL, and increased VLDL secretion (12). The attenuation of LPL activity is largely due to increased concentrations of apolipoprotein C-III, an endogenous inhibitor of LPL, observed in uremic states (33) .
Atherogenic dyslipidemia, a combination of moderate hypertriglyceridemia, prevalence of small dense LDL particles, and low HDL-C, is observed in 35% and 40% of individuals with diabetes mellitus type II (T2DM) and metabolic syndrome respectively (34, 35) . Insulin resistance associated with obesity, metabolic syndrome, and T2DM is a key predisposing factor for hypertriglyceridemia. Insulin plays a key role in the regulation of apolipoprotein (apo)B metabolism as it stimulates degradation of newly synthesized apoB, limiting VLDL formation (36) . However, derangements in the insulin signaling pathway leading to inhibition of apoB degradation is one of the proposed mechanisms for hypertriglyceridemia in insulin resistant states such as obesity, metabolic syndrome and T2DM. Furthermore, in the insulin resistant state, increased adipocyte lipolysis results in increased FFA flux to the liver which also fuels the lipidation of apoB leading to increased VLDL production and de novo hepatic lipogenesis (36) . This increased flux of FFA in the circulation also enhances intestinal chylomicron secretion leading to elevated TG levels (12).
In addition to the many secondary causes of raised triglycerides, mutations in at least six genes (LPL, APOA5, APOC2, LMF1 [lipase maturation factor-1], GPD1 [glycerol-3-phosphate dehydrogenase 1], GPIHBP1 [glycosylphosphatidylinositol-anchored high-density lipoproteinbinding protein-1]) involved with VLDL/chylomicron clearance can also result in severe hypertriglyceridemia (37) . A purely monogenic disorder is rare but should be considered when severe hypertriglyceridemia is present and first diagnosis dates back to early childhood. More commonly, the genetic basis for moderate to severe hypertriglyceridemia is polygenic, which can synergize with environmental factors to profoundly alter TG/VLDL production and clearance (38, 39) . Table 1 summarizes the genetic, non-genetic, and drug-related causes of hypertriglyceridemia. 
Triglyceride Metabolism
Circulating lipoproteins contain both cholesterol and TG. While HDL and LDL predominantly transport cholesterol, VLDL, chylomicrons, and their remnants are enriched in TG. These TGRL represent a heterogenous group of lipoproteins of varying size, density, protein cargo, and core lipid composition. TGRL are derived via two routes -an endogenous (hepatic) pathway and an exogenous (intestinal) pathway (Figure 1 ) (41) .
In the endogenous pathway, VLDL is produced in the endoplasmic reticulum of hepatocytes by constitutive synthesis of apoB100 with concomitant lipidation via microsomal triglyceride transport protein (MTP). The FFA for lipidation are derived from the circulation (FFA released from adipocytes and uptake of chylomicron or VLDL remnants) or newly synthesized in the liver (36) . Subsequently, a variety of apolipoproteins (apoproteins) are added to the surface of the nascent VLDL particle during secretion, including ApoCI, apoCII, apoCIII, and apoE. Once VLDL particles are secreted into the plasma, LPL along the luminal surface of capillaries hydrolyzes the TGs within the core of VLDL particles into FFA, which can then be taken up by myocytes and adipocytes. As FFA are liberated from VLDL, these TGRL are remodeled both physically (become smaller by shedding FFA and surface phospholipids) and chemically (become relatively cholesterol enriched) to become smaller and denser VLDL and intermediate density lipoprotein (IDL) particles (13,41). These IDL particles can be further catabolized to generate LDL. The constitutive production and regulation of hepatic apoB plays a key role in VLDL synthesis and secretion and safeguards against hepatic steatosis. On the other hand, genetic or therapeutic antagonism of apoB production can lead to hepatic steatosis through suppression of VLDL secretion (36) . Incomplete lipidation of apoB by MTP leads to its proteasomal degradation with subsequent decrease in VLDL production. Studies suggest that there are differential effects of apoB versus MTP inhibition on hepatic steatosis (42) . Rodent studies have demonstrated that inhibition of apoB synthesis did not increase hepatic steatosis compared to inhibition of MTP (42, 43) . The absence of hepatic steatosis with apoB inhibition is thought to be due to accumulation of lipids in the endoplasmic reticulum (ER) which stimulates ER autophagy, leading to fatty acid (FA) oxidation and protection from fat accumulation (42) . The long-term clinical consequences of hepatic steatosis due to pharmacologic apoB or MTP inhibition in humans remains unclear (44).
In the exogenous pathway, TGs are hydrolyzed to form fatty acids and 2monoacylglycerol in the stomach and proximal small intestine (13). The FFA and monoacylglycerols are then absorbed by enterocytes and incorporated into apoB48 containing chylomicrons. These chylomicrons are then secreted into the lymphatic system and enter the venous circulation via the thoracic duct where they acquire apoCII, apoCIII, and apoE (13). Once in the circulation, LPL along the luminal surface of capillaries hydrolyzes the TGs within the core of chylomicrons into FFA, which can then be taken up by myocytes and adipocytes in a manner analogous to that of VLDL particles. The smaller, cholesterol enriched chylomicron remnants are cleared from the circulation by binding to the LDL receptor or LDL receptorrelated protein-1 via apoE and the heparan sulfate proteoglycan pathway in the liver (13,41).
LPL, the central node in TGRL metabolism, is synthesized by several cells types including cardiomyocytes, adipocytes, and macrophages and must be then transported to the capillary lumen by an endothelial protein, GP1HBP1 (45), which also provides a platform for LPLmediated lipolytic processing along the capillary lumen (46). Maturation of LPL following synthesis is mediated by lipase maturation factor 1 (LMF 1) in the endoplasmic reticulum of parenchymal cells (eg, myocytes and adipocytes) (47). LPL plays a critical role in plasma TG clearance and therefore its enzymatic activity is highly regulated by various proteins including apoCI, apoCII, apoCIII, apoA-V, apoE, and the angiopoietin-like proteins ANGPTL3, ANGPTL 4 and ANGPTL 8 (13,48). It is important to note that although apoCIII is a potent inhibitor of LPL activation, recent studies have shown that it has a pleiotropic role in the regulation of TGRL metabolism independent of LPL pathways. These include inhibition of hepatic lipase activity and inhibition of hepatic TGRL remnant clearance (49). Table 2 summarizes the action of these proteins on LPL.
ADVANCE ARTICLE: Endocrine Reviews
A D V A N C E A R T I C L E
Measurement of Triglycerides and Remnant Cholesterol
As previously mentioned, TGRL encompass hepatically secreted (VLDL) and intestinally derived (chylomicrons) particles. The cholesterol content of partially lipolyzed TGRL, also called remnant cholesterol (RC), includes the cholesterol cargo of VLDL and IDL in the fasting state and of chylomicron remnants in the non-fasting state (as well as the altered fasting state in individuals with hypertriglyceridemia) (55). Clinically, plasma TG concentrations serve as a surrogate measure of TGRL and RC. Circulating plasma apoB-containing lipoproteins penetrate the endothelial cell lining of the artery wall in susceptible regions and enter the intimal space where they may be trapped by interaction with subendothelial proteoglycans (56,57). These retained apoB-containing lipoproteins can then be engulfed by arterial macrophages. Within macrophages, cholesterol cannot be metabolized and thus it accumulates, leading to engorged, dysfunctional foam cells. However, the TG are catabolized by macrophages and therefore do not accumulate in atherosclerotic plaque. Thus, the TG themselves, while possibly potentiating atherogenesis, may not directly lead to plaque formation. This suggests that the cholesterol content in TGRL (eg, RC), rather than the TGs, may be more important in atherogenesis, as it is known to accumulate in atherosclerotic plaque and is in the causal pathway of atherosclerosis. Therefore, an estimation of RC may be more important than the TG level itself. An estimate of RC can be calculated from a standard lipid profile as RC = total cholesterol minus LDL-C minus HDL-C. The Friedewald equation is generally used to calculate LDL-C. However, this approximation becomes completely unreliable when TG >500 mg/dL (58). The Friedewald equation assumes a fixed ratio of TG:VLDL-C of 5:1, however, the actual ratio varies across the range of TG and cholesterol levels (58). Newer methods estimate LDL-C levels using an adjustable factor for TG:VLDL-C ratio based on TG and non-HDL-C concentrations (59). Alternatively, direct LDL-C measurements can also be utilized in order to more accurately calculate RC in the setting of significantly elevated TG levels.
In addition to calculation methods, RC can be directly measured using a variety of analytical methods including ultracentrifugation, nuclear magnetic resonance (NMR) spectroscopy, and by a direct automated assay. The automated assay by Denka Seiken measures the cholesterol content in chylomicrons and VLDL remnants utilizing enzymes and surfactants (60). RC can also be measured by immunoseparation assays using antibodies to apoA1 and apoB100 (61,62). This immunoaffinity mixed gel containing apoA1 and B100 antibodies absorb almost all lipoproteins with the exception of certain subpopulations of TGRL (d<1.006 g/dl), specifically chylomicrons and VLDL remnants, which can then be quantified (61). The automated assay only measures a fraction (approximately 13%) of the calculated RC compared to the immunoseparation assay, which correlates better with the calculated levels (55,60). The vertical auto profile (VAP) method measures RC (IDL-C and VLDL-C) after separation of lipoproteins by density-gradient ultracentrifugation (63,64). The quantification of RC from the exogenous pathway (i.e. chylomicron remnants) can be done via ultracentrifugation or, indirectly, by measuring apoB48 (55,65,66). ApoB48 is the truncated gene product created by post-translational modification of the larger apoB100 and is found exclusively on chylomicrons and their remnants. (67). ApoB48 is primarily synthesized in the small intestine and plays a key role in chylomicron assembly. Each chylomicron and chylomicron remnant particle contains a single apoB48 molecule which can be used as a measure of intestinally-derived remnant cholesterol (67). At this time, these direct assays to measure RC have limited clinical applicability as they do not measure all RC in the plasma and are labor intensive and costly. Currently, there is an unmet need for the development of automated assays that accurately and reproducibly measure all RC, which may take on increased urgency if RC is ultimately vindicated as an important causal and targetable ASCVD risk factor. (11).
Fasting vs nonfasting measurement
Historically, lipid profiles have been measured in the fasting state, following an 8-12-hour period without food intake. Fasting provides sufficient time for catabolism of dietary TG (e.g., chylomicrons). Early epidemiologic studies demonstrated that fasting TG levels independently associated with CVD and correlated well with nonfasting TG levels (68,69). The use of the Friedewald equation for LDL-C estimation, which depends on fasting lipoprotein measurements, resulted in early guideline recommendations to use fasting lipid profiles (13,24,70). However, because most individuals eat regularly throughout the day and fast only for a few hours in a 24hour cycle (during sleep), nonfasting lipid levels may be a better indicator of plasma atherogenic lipoprotein concentrations when compared to fasting levels. Moreover, a robust evidence base has accumulated in recent years that also suggests that remnant lipoproteins are important contributors to atherosclerosis and development of CVD (71-78). In fact, postprandial TG concentrations have been shown to be an equal, if not superior, predictor of future CVD events compared to fasting levels (73, 74) . These studies accounted for the variability in postprandial TG concentrations through stratification by time since last meal and controlling for factors such as age, body mass index, diabetes, hormone use, menopausal status and ethnicity. In the postprandial period, both intestinally and hepatically derived lipoproteins can be measured in the circulation, representing a potentially more accurate reflection of the atherogenic lipoprotein burden in a 24-hour period (13,79). Compared to the fasting state, maximal mean changes in random, nonfasting lipoprotein levels are +26 mg/dL for TG, +8 mg/dL for RC, -8 mg/dL for total cholesterol, -8 mg/dL for LDL-C and -8 mg/dL for non-HDL-C, while HDL-C levels are generally unaffected in the general population (79). These postprandial changes in TGs depend on baseline TG levels, fat load in the meal, and time since the last meal (71,79,80). In most individuals, these differences in plasma fasting and nonfasting TG level are small in magnitude and therefore likely clinically insignificant. In general, consumption of a low-fat breakfast (<15 g of fat) before blood draw is unlikely to increase postprandial TG levels by more than 20% or levels that exceed 200 mg/dl in individuals with fasting TG levels<150 mg/dL (81, 82) . Thus, it may be reasonable to obtain a nonfasting lipid profile for a vast majority of patients in the general population given its advantages such as convenience and ease of sampling, lack of clinically significant difference in lipid levels and comparable efficacy in assessing and managing ASCVD risk compared to fasting lipid measurements (71). Accordingly, several current recommendations support the use of random, non-fasting lipid profile in clinical practice for cardiovascular risk prediction (2,12,71,83-85), although it is not clear as to how to use nonfasting lipids once treatment is started with lipid lowering therapy. 
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TGRLs and Atherosclerosis
If in fact TGs are causal in the atherosclerotic pathway, the exact underlying mechanisms by which they facilitate and participate in atherosclerotic plaque formation is unclear. Large TGrich chylomicrons and VLDL particles cannot penetrate the arterial wall to be retained within the subendothelial space and engulfed by vascular macrophages (86) (87) (88) . This notion is supported by studies of individuals with familial chylomicronemia syndrome due to LPL deficiency, whose TG are poorly degraded in plasma. Despite severe hypertriglyceridemia, these individuals do not develop atherosclerosis in the absence of other cardiovascular risk factors (89). On the other hand, TGRLs and their remnants are thought to be equally or more atherogenic than LDL. TGRLs can readily penetrate the arterial wall and are susceptible to retention by connective tissue matrix through interaction of the positively charged residues (arginine and lysine) on apoB with the negatively charged sulfate groups of subendothelial proteoglycans, similar to LDL. Once trapped in the subendothelial space, LDL particles must be modified (eg, oxidative modification) before they can be taken up by scavenger receptors on the surface of macrophages leading to the formation of foam cells and development of atherosclerotic plaque ( Figure 1 ) (56,90). On the other hand, TGRL can be taken up by arterial wall macrophages directly without oxidative modification (91). Moreover, remnants, due to their larger size, carry more cholesterol per particle than LDL (13). Endothelial dysfunction often precedes the development of atherosclerosis. TGRL remnants have been linked to impaired coronary vasomotor function, decreased brachial artery flowmediated dilatation, and increased carotid intima media thickness (92-94). Although the exact underlying mechanisms by which TGRL remnants promote endothelial dysfunction need to be elucidated, there are several proposed theories. TGRL remnants promote endothelial dysfunction through increased production of reactive oxygen species and induce endothelial cell apoptosis by increased secretion of tumor necrosis factor (TNF)-α and interleukin (IL)-1β (41, 95) . Furthermore, impairment of endothelium-dependent vasodilation and increased oxidative stress may also play a role in promoting endothelial dysfunction (96,97).
TGRL and Inflammation
LPL-mediated hydrolysis of TGRL produces lipolytic products such as oxidized FFA (41) . These FFA and TGRL remnants induce production of cytokines ( TNF-α), interleukins (IL-1, IL-6, IL-8), and proatherogenic adhesion molecules (intracellular adhesion molecule-1 and vascular cell adhesion molecule-1) that facilitate migration of leukocytes to the site of inflammation (98). Thus, this TGRL induced inflammatory response is characterized by monocyte adhesion to the endothelium and neutrophil activation (98,99). In addition to their proinflammatory effects, TGRL lead to activation of the coagulation cascade through assembly of the prothrombinase complex and upregulation of the expression of the plasminogen activator inhibitor-1 gene and the plasminogen activator inhibitor-1 antigen (86,100). Collectively, these processes lead to enhanced platelet aggregation and clot formation (41, 100) . It is still a matter of debate as to whether the cholesterol content of TGRL remnants primarily contributes to the progression of atherosclerosis, rather than the triglycerides themselves (101). Interestingly, Mendelian randomization suggests a causal association of elevated nonfasting remnant cholesterol with lowgrade inflammation and ischemic heart disease (IHD), while elevated LDL-C associates with IHD but not inflammation (102). Numerous epidemiological studies and meta-analyses demonstrate a positive association of TG with risk of ASCVD (68,103-106) ( Table 3 ). In particular, two prospective observational studies, the Copenhagen General Population Study and the Copenhagen City Heart Study, have provided significant insights into the association between TGs and ASCVD (74, 78, 107) . The Copenhagen City Heart Study enrolled 13,981 participants not on lipid lowering therapy and demonstrated that increasing levels of non-fasting TG levels were associated with increased risk of myocardial infarction (MI), IHD, and death in men and women over a 27-year follow-up (74). Non-fasting TG levels >5 mmol/L (440 mg/dL) were associated with a 4.6-fold and 16.8-fold increase in risk of MI for men and women, respectively, compared to TG levels <1 mmol/L (88 mg/dL). Similarly, increased levels of nonfasting TG levels were associated with a 3.2-fold and 5.1-fold increase in risk of ischemic stroke for men and women respectively (78) . The higher risk of events in women compared to men has been attributed to confounding from higher alcohol intake in men (11). A subsequent larger study of approximately 100,000 participants from the Copenhagen City Heart Study and the Copenhagen General Population Study demonstrated similar findings. Specifically, they found a 5.1-fold, 3.2-fold, 3.2-fold, and 2.2-fold increase in risk of MI, IHD, ischemic stroke, and all-cause mortality, respectively, for individuals with nonfasting TG > 6.6 mmol/L (580 mg/dL) compared to those with TG < 0.8 mmol/L (70 mg/dL) (101). More recently, Varbo et al demonstrated that higher concentrations of nonfasting TGs were associated with a stepwise increase in risk of heart failure with a multivariable hazard ratio of 2.59 (95% confidence interval, 1.48-4.54) for participants with nonfasting TG ≥ 5 mmol/L (440 mg/dL) compared to those with TG concentrations <1 mmol/L (88 mg/dL) (107) .
Epidemiologic Studies of Triglycerides and Risk of Cardiovascular Disease

ADVANCE ARTICLE: Endocrine Reviews
In the Women's Health Study, a prospective observational cohort of 26,509 healthy US women, nonfasting TG levels were associated with a 1.98-fold increase in risk of CVD events, independent of traditional risk factors, other lipids, and markers of insulin resistance (73) . However, fasting TG levels were not significantly associated with CVD events after adjustment for TC, HDL-C, and measures of insulin resistance (p-value=0.90). Interestingly, when stratified by time since last meal, TG measurements 2 to 4 hours postprandially had the strongest association with CVD events (4.48-fold increase in risk).
In an analysis by the Emerging Risk Factors Collaboration, including 302,430 individuals without known vascular disease from 68 long-term prospective studies with 2.79 million personyears of follow-up, fasting and nonfasting TG levels were associated with increased risk of coronary heart disease (CHD) (HR 1.37, 95% confidence interval, 1.31-1.42) after adjustment for nonlipid risk factors (72). However, the association was attenuated after adjustment for HDL-C and was found to be nonsignificant after adjustment for non-HDL-C. Additionally, TGs were not associated with stroke after adjustment for lipids. In this largest epidemiological study to date, the authors concluded that "for population-wide assessment of vascular risk, triglyceride measurement provides no additional information about vascular risk given knowledge of HDL-C and total cholesterol levels, although there may be separate reasons to measure triglyceride concentration (eg, prevention of pancreatitis)". While debate continued as to the relative importance of the relationship between TG and ASCVD, the investigative agenda for the next decade largely transitioned from TG to HDL-C as a potential causal risk factor for ASCVD and a potential target of therapy. Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin versus placebo on background statin therapy in individuals with established ASCVD failed to demonstrate a reduction in vascular events (18, 19) . Furthermore, three large RCTs of cholesterol ester transfer protein (CETP) inhibitors (CETPi) In an attempt to clarify the issue of causality, a number of genetic studies have provided important insights. Genetic studies, and in particular Mendelian randomization studies, provide a robust tool to establish causality as they capture a life-time effect of an exposure. DNA variants can be used to assess if a biological marker (e.g. TG) that has an epidemiological association for risk of disease (e.g. CHD) is likely causal for the disease. Therefore, if a DNA variant is known to have a direct influence on the biomarker level or activity of a protein that influences the biomarker level and that biomarker is causal for disease, then the DNA variant should be associated with the disease risk without the possibility of reverse causality (111) . The biomarker is likely not causal for the disease if similar association between the DNA variant and disease risk as seen in observational studies is not apparent (111) . As such, Mendelian randomization studies are an effective way to understand the causal role of TGRL and CVD. Mendelian randomization is essentially an RCT that has been performed by nature as there is a random allocation of alleles to offspring at the time of conception which is unaffected by reverse causation and independent of environmental and genetic confounders (111) . Consistent with these RCTs, Mendelian randomization studies further support the notion that HDL-C may not be causally related to CHD risk (111, 112) .
Given the failed HDL-C drug trials and new insights from the Mendelian randomization studies, it is now generally accepted that HDL-C, while associated with ASCVD, is not in the causal pathway. Thus, the pendulum has shifted back once again to a focus on TGRL and RC as potentially etiologic in atherosclerosis.
Several studies have also examined the relationship between RC (both calculated and measured) and ASCVD (60,64, 76, 102, [113] [114] [115] . Varbo et al. demonstrated that each 1 mmol/L (39 mg/dL) increase in nonfasting RC (calculated as total cholesterol minus HDL-C minus LDL-C) associated with a 2.8-fold increase in risk of IHD independent of low HDL-C (76) . In another study of 97,962 participants from the Copenhagen City Heart Study and the Copenhagen General Population Study, nonfasting calculated RC was associated with a stepwise increase in risk of IHD, MI, and all-cause mortality (113) . In the study by Jepsen et al., both elevated levels of measured and calculated RC were associated with all-cause mortality in patients with IHD (60). More recently, a nested-case control study of 4,662 individuals from the China Kadoorie Biobank demonstrated that RC concentrations (measured by NMR spectroscopy) were associated with a 1.27-fold increased risk of MI and 1.20-fold increased risk of ischemic stroke (108) . It is important to note that most of these observational epidemiologic studies were done in the prestatin era.
There are a number of studies (mostly post-hoc analyses) that have looked at the association between on-treatment TG levels and ASCVD risk. In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) study, on-treatment TG <150 mg/dL (<1.7 mmol/L) was independently associated with a lower risk of recurrent CHD events (HR 0.72, 95% CI 0.54 to 0.94; p = 0.017) in patients with acute coronary syndrome and LDL-C <70 mg/dL (109) . Similarly, a pooled analysis of the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) and TNT (Treating to New Targets) trials demonstrated that increased TG levels were associated with higher risk of CVD events in statin-treated patients, although the risk was attenuated after adjustment for HDL-C and apoB/apoA-I ratio (110) . The aforementioned observational epidemiology linking TG and RC to ASCVD is largely consistent. However, the possibility of residual confounding limits the ability to draw causal inference from these observational studies. In fact, one study in particular suggested that TG are not likely directly related to ASCVD after full adjustment with non-HDL-C (72). However, there is now general consensus that adjustment of TG by non-HDL-C is inappropriate. Specifically, non-HDL-C encompasses all apoB-containing lipoproteins (including VLDL, IDL, chylomicrons and their remnants) and elevated TG levels are closely linked to non-HDL-C with high intercorrelation between the variables. The method of Mendelian randomization has also been applied in this context in attempts to disentangle the association of TGRL and ASCVD. However, a well-known limitation of Mendelian randomization analyses is that they are susceptible to genetic pleiotropy. This phenomenon occurs when the gene variant under study affects more than one pathway and thus the observed association between the variant and disease risk may not be due to the biomarker of interest (111) . In particular, Mendelian randomization studies of variants associated with TG are commonly affected by the pleiotropic effects of single nucleotide polymorphisms (SNPs) on multiple metabolic pathways effecting plasma lipids, including HDL-C and LDL-C (111, 116) . These SNPs are primarily located on 6 genes associated with plasma TG levels (APOA5, APOC3, ANGPTL4, LPL, APOA4 and TRIB1) and CHD (111) . To overcome the effects of pleiotropy, Do et al. used multivariable Mendelian randomization to separate the effects of TG from LDL-C and HDL-C on CAD using 185 SNPs associated with blood TG, LDL-C, or HDL-C levels (117) . They found that the strength of a SNP's effect on TG levels correlated strongly with the magnitude of effect on CAD, after adjustment for the SNP's effects on LDL-C and HDL-C. This finding supported the notion that plasma TG levels are an independent causal risk factor for CAD (117) . In another Mendelian randomization analysis of 10,208 individuals from the Copenhagen City Heart Study, genetically lower concentrations of nonfasting plasma TGs were associated with reduced all-cause mortality (118) . Using a multiple SNP instrumental variable meta-analysis approach, Holmes et al. demonstrated an independent causal association between TG and CAD (6).
Genetic Studies of Triglycerides and Cardiovascular Disease
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Furthermore, insights from variants in genes involved in plasma TGRL metabolism, namely LPL and those that modulate its function, including apolipoprotein A-V (APOA5), apolipoprotein CIII (APOC3), ANGPTL 3 and ANGPTL 4 are also associated with ASCVD (19, 76, 77, 111, [119] [120] [121] [122] [123] [124] [125] . Increased RC levels due to mutations in APOA5, an activator of LPL, is associated with a 2.2-fold increased risk of MI (77) . Loss-of-function (LOF) mutations in APOC3 are associated with reduction in both plasma TGs and ASCVD risk (19, 121, 122, 126) . In one study, LOF APOC3 mutations were associated with 39% lower TG levels and 40% lower risk of CHD (OR 0.60; 95% CI 0.47-0.75, P=4x10(-6)) (19). Thus, apoCIII is a promising target for pharmacologic modulation of TGRL metabolism. Currently, there are numerous therapeutic approaches to antagonize its action at various phases of clinical development.
LOF mutations leading to complete deficiency of ANGPTL3 is associated with a familial combined hypolipidemia, characterized by extremely low circulating LDL-C, HDL-C and TG levels (124, 127) . In three wild-type first degree relatives with complete ANGPTL3 deficiency, computed tomography angiography showed no evidence of coronary atherosclerotic plaque (124) . Heterozygous carriers of ANGPTL3 LOF mutations had a 17% reduction in circulating TG levels, a 12% reduction in LDL-C levels, and a 34% reduction in odds of CAD (OR 0.66; 95% CI 0.44-0.98; p=0.04) (124) . As is the case with apoCIII, drugs are being developed to inhibit ANGPTL3 either at the gene or protein level. LOF variants in ANGPTL4, which codes for a protein that inhibits LPL action, is associated with both reduced plasma TG levels and CHD risk (HR 0.63, 95% CI, 0.45-0.89) (123) . Similarly, carriers of the E40K variant in ANGPTL4 had a 19% lower risk of CAD compared to noncarriers (128) . To our knowledge, there have been no human trials of pharmacological agents targeting ANGPTL4. LOF mutations in LPL are also associated with increased plasma TG and risk of ASCVD (129, 130) . Conversely, carriers of the gain-of-function LPL variant (S447X) have lower TG levels and lower incidence of ASCVD (131) .
Overall, this data suggests that elevated TG levels, as a surrogate measure of TGRL, are an independent causal risk factor for ASCVD. Future therapies directed at enhancing LPL and ApoAV function or decreasing APOCIII and ANGPTL3 function may have a role in mitigating the risk of ASCVD associated with TGRL.
TG lowering therapies
Lifestyle changes, including dietary modification (reduction of carbohydrate and fat intake), exercise, reduction of alcohol intake, and weight loss, are the mainstay for management of hypertriglyceridemia. Collectively, these interventions can reduce plasma TG levels by up to 60% (38) . Several pharmacologic options to lower plasma TG are available and can be used as an adjunct to lifestyle interventions. Although statins are the cornerstone for treatment of LDL-C and its attendant ASCVD risk, they are associated with dose-dependent reduction in TG by 22-45% in individuals with baseline hypertriglyceridemia (132) . Currently, three other classes of drugs are available for the management of hypertriglyceridemia: fibrates, niacin, and omega-3 fatty acids. Table 4 summarizes the approximate reduction in TG concentrations that can be achieved with lifestyle and pharmacologic interventions.
Fibrates
Fibrates or fibric acid derivatives exert their lipid-modifying effects by activating the peroxisome proliferator-activated receptor (PPAR)-α, a nuclear receptor that increases expression of LPL, apoAI, and other lipid-related genes (13). In general, treatment with fibrates lower TG levels by 30-50%, depending on baseline plasma concentrations (15) . Several studies have evaluated the efficacy of fibrates in reducing adverse outcomes, however, results have been variable. In the Helsinki Heart Study, gemfibrozil reduced the risk of incident CHD by 32% without any significant effect on stroke, cardiovascular mortality, or all-cause mortality compared to placebo (14). The VA-HIT (the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial) demonstrated that gemfibrozil was associated with a 24% reduction in the combined endpoint of CHD death, non-fatal MI, and stroke compared to placebo in 2531 men with CHD and HDL-C ≤ 40 mg/dL (137) . Again, there was no significant difference in all-cause mortality. The FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study with fenofibrate failed to demonstrate a reduction in the rate of the composite primary outcome (CHD death and nonfatal MI) compared to placebo but was associated with a reduction in total CV events (24% reduction in nonfatal MI and 21% reduction in revascularization) (138) . Similarly, the BIP (Bezafibrate Infarction Prevention) study did not exhibit clinical benefit of bezafibrate compared to placebo for the primary composite outcome (fatal or nonfatal MI or sudden death) in patients with CHD (139) . Although results from these individual fibrate monotherapies have been inconsistent, post-hoc analyses of subgroups with atherogenic dyslipidemia (low HDL-C and high TG) suggest benefit in those with overt hypertriglyceridemia (TG >200 mg/dL) (139) (140) (141) (142) (143) . Subsequent meta-analyses have also demonstrated similar findings regarding the benefits of fibrates in patients with true dyslipidemia (144) (145) (146) .
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In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, addition of fenofibrate to statin therapy did not result in significant beneficial effects on CVD risk (147) . However, as seen with the fibrate monotherapy trials, a subgroup of patients with atherogenic dyslipidemia may have derive cardiovascular benefit from the combination of fenofibrate and simvastatin (147) . It is important to note that most subjects in the large fibrate trials exhibited baseline TG levels<200 mg/dL and thus the results are not definitive.
Omega-3 Fatty Acids (OM3FA)
OM3FA also play an essential role in cellular membrane formation and stability and serve as precursors for inflammatory mediators (eicosanoids, prostaglandins, protectins, resolvins, leukotrienes) (148) . At therapeutic doses of 2-4 grams per day, marine derived OM3FA (eicosapentaenoic acid [EPA]+ docosahexaenoic acid [DHA] or EPA alone) reduce blood TG concentrations by up to 30-50% depending on baseline levels (28) . The TG lowering is linear with a dose-dependent effect such that greater absolute reduction is seen in individuals with higher baseline TG levels (149) . TG reduction is mediated by multiple mechanisms including increased fatty acid catabolism by peroxisomal β-oxidation, decreased hepatic lipogenesis, and increased clearance of plasma TGs (150) . In addition to their TG lowering effects, OM3FA improve vascular function, lower inflammation, decrease platelet aggregation, exert antiarrhythmic effects, and reduce hepatic steatosis and insulin resistance (149) .
Prescription OM3FA formulations are available as ethyl esters or free fatty acid forms with varying amounts of EPA+DHA or EPA alone (151) . The free fatty acid formulation has greater bioavailability compared to the ethyl esters (152) . Both EPA and DHA formulations lower TGs, non-HDL-C, and apoB levels. However, EPA-only formulations do not increase LDL-C levels compared to DHA containing formulations (150) . Similar to the cardiovascular outcomes studies with fibrates, studies of OM3FA have demonstrated inconsistent results. However, it is important to emphasize that these disparate findings may be due to the inclusion of subjects with normal baseline TG levels (<150 mg/dL) and use of different formulations, concentrations, and doses of OM3FA (150, (153) (154) (155) (156) (157) . In a subgroup of patients with TG ≥ 1.70 mmol/L (≥ 150 mg/dL), OM3FA supplementation demonstrated beneficial effects on cardiovascular outcomes (RR 0.82, 95% CI 0.74-0.91, P=0.006) compared to lower TG levels (157) . Furthermore, JELIS (Japan EPA Lipid Intervention Study), an open-label blinded study of supplementation with 1.8g/day EPA with statin (pravastatin 10 mg or simvastatin 5 mg) versus statin alone, demonstrated a statistically significant (p=0.01) 19% reduction in major coronary events (158) . In a subanalysis of JELIS evaluating individuals with TG≥150 mg/dL and HDL-C <40 mg/dL, EPA treatment led to a 53% reduction in incident CAD (HR 0.47; 95% CI 0.23-0.98; p=0.043) (159) . Compared to the dose of OM3FA used in the JELIS study (1.8g/day), the average dose of OM3FA in other RCTs has generally been 1g/day, an amount that will not significantly lower TG levels and may therefore explain their inconsistent results (151) .
Several ongoing cardiovascular outcomes trials with different formulations and higher doses of OM3FA are currently underway ( Table 5 ). Icosapent ethyl (Vascepa; Amarin), a highly purified EPA only formulation, lowers plasma TG by 10-33% at doses of 2-4g/day without any significant increase in LDL-C levels (165) . REDUCE-IT [Reduction of Cardiovascular Events With EPA-Intervention Trial] is evaluating the efficacy of Icosapent ethyl for prevention of adverse ASCVD outcomes and the results are expected to be presented at the American Heart Association Scientific Sessions in November 2018. Epanova (omega-3-carboxylic acids; 
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Niacin
Niacin, or nicotinic acid, can reduce TG levels by up to 30%. It inhibits adipose tissue lipolysis which reduces the flux of FFA to the liver and therefore leads to reduced hepatic VLDL synthesis (167) . The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health) study was a large randomized controlled trial that evaluated the efficacy of extended release niacin in addition to statin therapy for reduction of ASCVD events (18) . Despite reduction in TG levels by 28.6%, no incremental benefit in the primary end point was observed from the addition of niacin to statin therapy and thus the trial was terminated early. In the HPS2-THRIVE study, addition of niacin to statin therapy did not reduce the risk of major vascular events despite mean reductions in TG levels of 33 mg/dL compared to placebo (19). Due to the lack of benefit in reducing CV events and high incidence of adverse effects, the use of niacin is limited in clinical practice. It should be pointed out, however, that similarly to fibrate and OM3FA trials, neither of these large niacin trials sought to recruit patients with hypertriglyceridemia. Also similar to the fibrate and OM3FA trials, a post-hoc analysis of AIM-HIGH evaluated the impact of niacin on a dyslipidemic subgroup (high ≥TG 200 mg/dL and low HDL-C <32 mg/dL) and demonstrated a 37% reduction in cardiovascular events in the niacin group (HR=0.64, p-0.032) (168) .
Emerging TG lowering therapies
Insights from genetic studies has led to a new, and perhaps more intelligent, approach to therapeutic drug targeting. In particular, antisense oligonucleotide (ASO) and small interfering RNA (siRNA) technologies, which employ gene silencing strategies through specific mRNA degradation, are currently being pursued as therapeutic approaches to lower TG and RC levels (169) . Gene silencing technologies have been developed around the principle that DNA is transcribed into mRNA, which is then translated into protein. ASO (a single strand of RNA) or siRNA (a double strand of RNA) can be synthesized to bind the mRNA product of a gene that is known to influence levels of plasma lipoproteins (e.g. TG) and prevent their expression through RNA cleavage or inhibition of translation; therefore, silencing, or turning off, the gene (169) . To improve their targeting and potency, as well as reduce the potential for adverse effects, ASO or siRNAs can be attached to n-acetylgalactosamine (GalNAc) moieties to facilitate selective delivery to and uptake by hepatocytes through the asialoglycoprotein receptor (169) .
Volanesorsen (previously known as ISIS-APOCIII RX ) is a second generation ASO developed to inhibit apoCIII. It binds to the APOC3 messenger RNA and promotes its degradation, thereby inhibiting apoCIII synthesis in the liver (170) . Following preclinical and phase I studies, this was tested in three patients with familial chylomicronemia syndrome (FCS), a rare autosomal recessive disorder caused by mutations in LPL (or associated cofactors) leading to very severe hypertriglyceridemia, recurrent pancreatitis, and other complications leading to fatal events (49,171). All three of these patients had essentially no LPL activity (<5% of normal), yet demonstrated robust reductions in plasma apoCIII (70-90%) and TG (56-86%) levels in addition to reductions in apoB48, VLDL particle number, apoE, and non-HDL-C (49). These findings were surprising to many and challenged the canonical view of apoCIII as primarily an inhibitor of LPL. We now understand apoCIII as a pleiotropic regulator of TGRL metabolism through both LPL-dependent and LPL-independent pathways (49). In a subsequent phase 2 study, Volanesorsen reduced apoCIII levels by 80% with a concomitant reduction in TG level by up to 71% with an associated increase in HDL-C of 46% in a dose-dependent manner (170) . The COMPASS and APPROACH studies are currently testing Volanesorsen in a phase III clinical trial program (Table 5) . Volanesorsen is currently being evaluated by the FDA as an orphan drug for FCS. As reviewed earlier, ANGPTL3 is an endogenous inhibitor of LPL and loss-of-function variants have been associated with decreased TG, LDL-C, and HDL-C levels. Evinacumab (REGN1500, Regeneron), a human monoclonal antibody against ANGPTL3 reduced fasting TG levels by up to 70% and LDL-C levels by up to 23% in an early-phase trial (125) . Similarly, a phase 1 randomized, double-blind, placebo-controlled trial of an ASO targeting hepatic ANGPTL3 (IONIS-ANGPTL RX , Ionis Pharmaceuticals) messenger RNA lowered TG levels by up to 63% and LDL-C by up to 33% (164) . These studies highlight the potential of these two new therapeutic targets to lower plasma TG levels (Table 5) .
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Icosabutate, a synthetic OM3FA, is under clinical development and appears to be a promising option for lowering TG levels. In a study of 140 patients on stable statin therapy and residual elevations in TG ranging from 200 mg/dL-500 mg/dL, treatment with icosabutate reduced TGs by 27%, VLDL-C by 32% and apoCIII by 23% compared to placebo. LDL-C levels did not change significantly and HDL-C levels increased by 10% (163) .
Another novel agent for lowering TG levels is alipogene tiparvovec (AAV1-LPLS447X). This is a nonreplicating adeno-associated viral vector that delivers copies of the human LPL gene to muscle tissue. In clinical trials, intramuscular injection of alipogene tiparvovec was associated with reduction in the incidence of pancreatitis and was well tolerated (172) . Remarkably, this therapy was approved in Europe for patients with familial LPL deficiency but was ultimately pulled from the market given its prohibitive expense and attendant lack of uptake.
Pemafibrate, a selective PPAR-α modulator, is a novel compound currently under investigation for the treatment of hypertriglyceridemia in the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Diabetic Patients) trial. This large randomized placebo-controlled trial will examine the efficacy of pemafibrate versus placebo on cardiovascular outcomes in approximately 10,000 high-risk diabetic patients with hypertriglyceridemia and low HDL-C on concomitant statin therapy (173, 174) .
Conclusion
It is established that LDL is the primary causal factor in the development of atherosclerosis. As such, treatment targeting LDL-C remains a cornerstone for primary and secondary prevention of ASCVD. However, despite substantial reduction in atherosclerotic risk with statins and additional LDL-C lowering therapies, patients continue to be at a significant residual risk for recurrent events. Findings from observational and genetic epidemiology are consistent and strongly support a causal role of TGRL and/or RC as a risk factor for ASCVD. These insights have ushered in an exciting new era of precise therapeutic targeting. Many of these novel investigational agents are in late stage development with proof of impressive TG lowering efficacy. The results of the ongoing randomized controlled trials testing their impact on cardiovascular outcomes are eagerly awaited and are poised to answer the question as to whether TGRL drive ASCVD and whether they should be targeted therapeutically. Maggi Triglyceride rich lipoproteins (TGRL) are derived from an endogenous pathway through the liver and an exogenous pathway through the small intestines. In the endogenous pathway, very-low density lipoprotein (VLDL) is produced in the hepatocytes from free fatty acids (FFA) derived from the circulation or newly synthesized in the liver. A variety of apolipoproteins (apos) are On-treatment TG <150 mg/dl were associated with lower CHD risk compared with higher TG (HR 0.80, 95% CI 0.66 to 0.97; p = 0.025) after multivariable adjustment For each 10-mg/dl lowering in on-treatment TG, the incidence of death, MI, and recurrent ACS was lower by 1.6% (p<0.001) or 1.4% (p=0.01) after adjustment for LDL-C or non-HDL-C respectively
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IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) and TNT (Treating to New Targets) trials (110)
Post-hoc analysis of 2 prospective, randomized, multicenter studies comparing the efficacy of moderate and high-intensity statin therapy for prevention of recurrent Patients in the highest quintile of TG concentration had a higher risk of cardiovascular events compared to the lowest quintile (HR 1.63, 95% CI 1.46-1.81) After adjustment for HDL-C and apoB/ApoA-1, the relationship between TG and cardiovascular events was attenuated (HR 1.19, 95% CI 1.06 to 1.35, for fifth vs first quintile) TNT -atorvastatin 80 mg versus atorvastatin 10 mg; Median follow-up of 4.9 years; n=8,547
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After further adjustment for other risk factors (diabetes, body mass index, glucose, hypertension and smoking) the relationship between TG and cardiovascular events was non-significant (HR 1.10, 95% CI 0.97 to 1.24, for fifth vs first quintile) TG, triglycerides; CHD, coronary heart disease; OR, odds ratio; CI, confidence interval; MI, myocardial infarction; IHD, ischemic heart disease; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; US, United States; HDL-C, high-density lipoprotein cholesterol; RLP-C, remnant lipoprotein cholesterol; IDL-C; intermediate density lipoprotein cholesterol; SD, standard deviation; ACS, acute coronary syndrome; Apo, apolipoprotein (38, 133, 134) • 0.27 mg/dL per kg weight loss • 5-10% reduction in initial body weight reduces TG levels by 25% Dietary Modification (38, 135, 136) • 0.18 mmol/l (15.7 mg/dL) reduction in plasma TG levels with a plant-based protein and unsaturated fat enriched diet • 10-15% reduction in plasma TG levels with Mediterranean diet Exercise (38) • up to 20% reduction in plasma TG levels with moderate to intense aerobic exercise • ~5% reduction in plasma TG levels with resistance training Pharmacotherapy Statins (132)
• Dose-dependent reductions in TG of 22-45% in individuals with baseline TG>250 mg/dL • Minimal reduction in TG in individuals with baseline TG<150 mg/dL Fibrates (15) • 30-50% Niacin (15) • up to 30% Omega-3 Fatty Acids (15) • 30-50% TG; triglyceride. Divide mg/dL by 89 to convert to mmol/L. 
